Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer

Liang Shi¹, Qiyi Meng¹, Li Tong¹, Hongxia Li¹, Yujie Dong², Chongyu Su³ and Zhe Liu¹*

¹Department of Medical Oncology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China, ²Department of Pathology, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China, ³Department of Thoracic Surgery, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, Beijing, China

Background: Several randomized studies have shown that the combination of programmed cell death 1 (PD-1) inhibitor and chemotherapy is efficacious as a treatment for advanced non-small-cell lung cancer (NSCLC). However, in the neoadjuvant setting, there is scarce evidence of the effectiveness and safety of the combinations in squamous NSCLC. We conducted a retrospective study to evaluate neoadjuvant PD-1 inhibitor plus chemotherapy in resectable squamous NSCLC.

Methods: Patients from Beijing Chest Hospital, Capital Medical University, between October 2019 and October 2021, treated with PD-1 inhibitors and chemotherapy for resectable squamous NSCLC were retrospectively studied. The primary objectives were to assess the pathological tumor response and safety of neoadjuvant PD-1 inhibitors and chemotherapy.

Results: 63 patients with resectable squamous NSCLC stage IIA-IIIB were included. Two to four cycles of PD-1 inhibitors (37 cases with camrelizumab, 11 cases with toripalimab, 8 cases with tislelizumab, and 7 cases with sintilimab) and chemotherapy were administered prior to surgery. 42 patients (66.7%) achieved a major pathologic response (MPR), including 25 (39.7%) with a pathologic complete response (pCR). Twenty-one patients (33.3%) experienced grade 3 neoadjuvant treatment-related adverse events (TRAEs), and no patient had grade 4 or 5 TRAE.
Conclusion: Neoadjuvant PD-1 inhibitors and chemotherapy are feasible therapies for resectable squamous NSCLC. It was associated with a 66.7% MPR rate, 39.7% pCR rate, and tolerable toxicity.

KEYWORDS: resectable non-small-cell lung cancer, squamous cell carcinoma, neoadjuvant chemoimmunotherapy, programmed death-1 inhibitors, pathologic response

Introduction

In non-small-cell lung cancer (NSCLC), squamous NSCLC (sqNSCLC) represents approximately 25% to 30% (1), and it is associated with a shorter survival time than nonsquamous NSCLC (2, 3). Squamous NSCLC has historically been treated almost exclusively with cytotoxic chemotherapy due to the lack of targetable aberrations (4).

Patients with resectable NSCLC at high recurrence risk may benefit from neoadjuvant or adjuvant chemotherapy; however, the 5-year overall survival (OS) gain is only 5% (5, 6). Inhibitors of programmed death receptor 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1) are effective in the treatment of advanced squamous and nonsquamous NSCLC (7–11). These PD-1/PD-L1 inhibitors are evaluated in multiple clinical trials, rapidly moving from advanced NSCLC to resectable stages and from palliative to curative strategies.

Single-arm phase 2 studies with immunotherapy agents as monotherapy or in combination have recently shown encouraging outcomes (pathologic complete response, event-free survival, and OS) in the neoadjuvant setting (12–16). CheckMate 816 is a randomized, phase 3, open-label study evaluating nivolumab-plus-chemotherapy versus chemotherapy as neoadjuvant treatment for resectable NSCLC. The CheckMate 816 showed statistically significant improvements in the primary endpoints of event-free survival (EFS, median EFS was 31.6 months in the nivolumab-plus-chemotherapy arm and 20.8 months in the chemotherapy-alone arm; hazard ratio, 0.63; 97.38% CI, 0.43 to 0.91), and the pathologic complete response (pCR, pCR rate was 24% in the nivolumab-plus-chemotherapy arm and 2.2% in the chemotherapy-alone arm, odds ratio, 13.94; 99% CI, 3.49 to 55.75) (17). As a result of CheckMate 816, the FDA approved using nivolumab in combination with platinum-doublet chemotherapy for resectable NSCLC patients in the neoadjuvant setting, but in China, this strategy has not yet been approved.

However, in neoadjuvant therapy for NSCLC, few clinical studies on neoadjuvant treatment are designed for squamous cell carcinoma. Therefore, there is scarce evidence of the effectiveness and safety of the neoadjuvant chemoimmunotherapy in squamous NSCLC, especially in several ones approved in China for first-line treatment in advanced sqNSCLC (18–20). In addition, the pathological response of neoadjuvant chemoimmunotherapy in squamous cell carcinoma is not clear. Therefore, we conducted a retrospective study to evaluate pathological response and safety of neoadjuvant PD-1 inhibitor plus chemotherapy in resectable squamous NSCLC.

Materials and methods

Patient population

Patients from Beijing Chest Hospital, Capital Medical University, treated with PD-1 inhibitors and chemotherapy for resectable sqNSCLC between October 2019 and October 2021, were retrospectively studied. The inclusion criteria were as follows: age 18 years or older, confirmed histological diagnosis of sqNSCLC, Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2, clinical stage IIA-IIIB before the treatment, and ≥2 neoadjuvant treatment cycles, adequate organ function and undergone surgical resection. The exclusion criteria were as follows: had previous treatment before diagnosis or lacked completed radiological or pathological data. The resectable criteria were followed by defining the resectability status of the National Comprehensive Cancer Network (NCCN) Guidelines for all stage II A-IIIA cases. In terms of stage IIIB patients, the cases including tumor T3/T4 with single-station non-bulky N2 disease of mediastinal lymph nodes, excluding tumor T3/T4 with multi-station N2 disease or bulky N2 disease, were judged as potentially resectable or marginal resectable. Therefore, only cases that met the resectable criteria were administrated for neoadjuvant chemoimmunotherapy. Finally, 63 patients were included in the study (Figure 1). The study was carried out following the Declaration of Helsinki (as revised in 2013). It was reviewed and approved by the institutional review board (IRB)/ethics committee of Beijing Chest Hospital, Capital Medical University. In the neoadjuvant chemoimmunotherapy for operable NSCLC of this study, all PD-1 inhibitors were given for off-label use. All patients
were fully informed and signed informed consent before starting treatment.

The collected clinicopathologic data of the patients included sex, age, smoking history, ECOG PS, PD-L1 expression (22C3 PD-L1 antibody, Dako, Denmark), clinical TNM (cTNM) stage, neoadjuvant treatment regimen, treatment cycle, surgical treatment, radiological and pathological efficacy evaluation, and treatment-related adverse events (TRAEs). In addition, clinical TNM was determined according to the 8th edition of the lung cancer staging system of the American Joint Committee on Cancer (21).

Treatment regimen and surgery

All of the included patients were scheduled to receive surgery within 4-6 weeks after neoadjuvant chemoimmunotherapy that consisted of 2-4 cycles of a conventional platinum-based doublet chemotherapy regimen with PD-1 inhibitor on day 1 of each 21-day cycle. Patients received one of the following PD-1 inhibitors intravenously as neoadjuvant immunotherapy: camrelizumab (200 mg), toripalimab (240 mg), tislelizumab (200 mg), or sintilimab (200 mg).

As per standard institutional procedures, all surgical resections were performed with thoracotomy or video-assisted thorascopic surgery.

Treatment evaluation

The primary objectives were to assess the pathological tumor response of neoadjuvant PD-1 inhibitors and chemotherapy. The pathological tumor response endpoints were MPR, defined as ≤10% residual viable tumor cells in the primary tumor and sampled lymph nodes, and pCR, defined as the complete absence of residual viable tumor cells in the primary tumor and sampled lymph nodes (22).

Secondary endpoints were the imaging response and safety profile of the combination.

Contrast-enhanced CT scans were repeated to assess objective imaging response within seven days before surgery. The imaging responses were evaluated for all patients per the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (23), and the therapeutic response was considered as complete response (CR), partial response (PR), stable disease (SD), or progression disease (PD). The safety endpoints included
treatment-related adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE, v.5.0).

**Statistical analysis**

All statistical analyses were performed with Stata version 17.0 (StataCorp, TX, USA) or GraphPad Prism version 9.0 (GraphPad Software Inc., CA, USA). Frequency tabulation and summary statistics for the patient’s baseline characteristics, surgical outcomes, and safety evaluation provided data distribution characteristics. Continuous variables were expressed as medians with ranges. Categorical variables were expressed as numbers with percentages. The association of baseline characteristics and pathological response were conducted with the Fisher’s exact test. The association between the clinical response and the pathological response was performed with Pearson correlation coefficient analysis. A two-sided p value less than 0.05 was considered statistically significant.

**Results**

**Patient characteristics**

Sixty-three patients with resectable squamous NSCLC stage IIA-IIIB were included (Table 1). Of these patients, eight were females and 55 males aged from 47 to 75 years old (median age of 63 years old). Most patients (73.0%) had stage IIIA to IIIB disease, according to the IASLC eighth edition of the TNM Classification for Lung Cancer. PD-L1 expression before treatment was detected by the PD-L1 IHC 22C3 pharmDx assay. For the 40 patients with available PD-L1 data, 32 patients (50.8%) had a PD-L1 tumor proportion score of 1% or higher.

**Neoadjuvant treatment and imaging efficacy**

Two to four cycles of PD-1 inhibitors (37 cases with camrelizumab, 11 cases with toripalimab, 8 cases with tislelizumab, and 7 cases with sintilimab) and chemotherapy were administered prior to surgery (Table 1). The clinical activity of the chemoimmunotherapy neoadjuvant combination was evaluated according to the RECIST v.1.1 criteria. In particular, 43 out of the 63 cases achieved a partial response (PR, 68.3%), while 20 patients presented a stable disease (SD, 31.7%).

**Surgical treatment and pathological efficacy**

All 63 patients received R0 surgical resection. The results for surgical treatment are shown in Table 2. Surgical methods included video-assisted thoracoscopic surgery (VATS) (n=32) and thoracotomy (n=31), including 47 (74.6%) lobectomy, 9 (14.3%) bilobectomy and 7 (11.1%) pneumonectomy. The median days of hospitalization after surgery operations was 10 (range, 1–68), the median operation time was 154 (range, 85–310) minutes, and the median amount of estimated blood loss was 150 mL (50–1100 mL). One patient died within 48 hours of lobectomy. He had a clinical T3N2 primary tumor. Radiographic SD was observed after two cycles of neoadjuvant chemoimmunotherapy, which resulted in a technically challenging resection. The patient developed severe hypoxemia, required ventilator support, and died 48 hours postoperatively.

In total, 42 patients (66.7%) achieved a major pathologic response (MPR), including 25 (39.7%) with a pathologic complete response (pCR) in the primary tumor and sampled lymph nodes. In two patients, the primary tumor disappeared, but the regional lymph node involvement persisted, achieving an MPR in the final overall evaluation.

The waterfall plot shows pathological regression in the resected primary lung tumor after neoadjuvant administration, according to the subgroup of sex, smoking status, clinical TNM stage, PD-L1 expression, PD-1 inhibitor regimen, and RECIST response (Figure 2). There was correlation between the imaging regression and pathological regression (Spearman correlation coefficient = 0.43; P = 0.0004; Figure 3). The MPR was related to the clinical lymph nodal stage (Fisher’s exact test P = 0.009) and clinical TNM stage (Fisher’s exact test P = 0.027). The pCR was only related to the clinical TNM stage (Fisher’s exact test P = 0.047, Table 3). The Sankey diagram shows the degree of relationship between the pathological response of neoadjuvant therapy in different clinical stages (Figure 4).

**Safety**

Treatment-related adverse events were reported for 62 (98.4%) patients treated with neoadjuvant PD-1 inhibitors plus chemotherapy. Most of the adverse events were in grades 1-2. Grade 3 treatment-related adverse events occurred in 21 (33.3%) patients, including decreased neutrophil count 11 (17.5%) patients, pneumonia 7 (11.1%), and decreased white blood cell count 5 (7.9%), (Table 4). No grade 4-5 toxicities occurred during the neoadjuvant treatment phase.
Discussion

Resectable sqNSCLC is usually treated with a combination of surgery, radiation, and systemic chemotherapy. However, it has been proven that immunotherapy is a very effective front-line treatment for advanced sqNSCLC (8, 11, 18–20). Additionally, perioperative immunotherapy has been proven successful in NSCLC (13, 17, 24), but the effect of chemoimmunotherapy in resectable sqNSCLC has rarely been reported. In this study, we retrospectively analyzed 63 squamous NSCLC with stage II-IIIB treated with neoadjuvant chemoimmunotherapy. Our study revealed that PD-1 inhibitors plus chemotherapy were prescribed preoperatively, thus resulting in 66.7% (42/63) of patients achieving an MPR and 39.7% (25/63) cases achieving a pCR. Meanwhile, no unexpected adverse reactions were observed.

| Characteristic                  | Value or No. of Patients | %      |
|--------------------------------|--------------------------|--------|
| Patients                       | 63                       |        |
| Age, years                     | Median 63, Range 47-75   |        |
| Sex                            | Female 8, Male 55        | 12.7%  |
| Smoking status                 | Never 17, Current/Former 46 | 27.0% |
| ECOG PS                        | 0 39, 1 24              | 61.9%  |
| Clinical T stage               | T1 3, T2 20, T3 22, T4 18 | 4.8%, 31.7%, 34.9%, 28.6% |
| Clinical N stage               | N0 18, N1 17, N2 28     | 28.6%, 27.0%, 44.4% |
| Clinical stage (8th edition)   | IIA 3, IIB 14, IIIA 31, IIIB 15 | 4.8%, 22.2%, 49.2%, 23.8% |
| PD-L1 expression              | Positive (≥1%) 32, ≥1%-49% 13, ≥50% 19, Negative (<1%) 8, NA 23 | 50.8%, 20.6%, 30.2%, 12.7%, 36.5% |
| Neoadjuvant PD-1 inhibitor regimen | Camrelizumab 37, Toripalimab 11, Tislelizumab 8, Sintilimab 7 | 58.7%, 17.5%, 12.7%, 11.1% |
| Neoadjuvant treatment cycles   | 2 41, 3 18, 4 4 | 65.1%, 28.6%, 6.3% |

ESOG PS, Eastern Cooperative Oncology Group performance score; NA, not applicable; PD-1, programmed death 1; PD-L1, programmed death-ligand 1.

TABLE 2 Surgical outcomes.

| Surgical outcomes                                      | Patients (n=63) |
|--------------------------------------------------------|----------------|
| Operation time (minutes)                               | Median 154, Range 85-310 |
| Hospitalization after surgery (days)                   | Median 10, Range 1-68 |
| Estimated blood loss (mL)                              | Median 150, Range 50-1100 |
| R0 resection, n (%)                                     | Yes 63 (100%), No 0 (0%) |
| Extent of resection, n (%)                             | Lobectomy 47 (74.6%), Bilobectomy 9 (14.3%), Pneumonectomy 7 (11.1%) |
| Surgical methods, n (%)                                | Video-assisted thoracoscopic surgery 32 (50.8%), thoracotomy 31 (49.2%) |
| Perioperative death, n (%)                             | 1 (1.6%) |

Shi et al. 10.3389/fonc.2022.956755
Our findings further confirmed the findings of previous small samples of neoadjuvant immunotherapy for lung squamous carcinoma (27, 28).

A major pathological response is more likely to be observed in patients with squamous cell carcinoma (26%) than in those with adenocarcinoma (12%) following neoadjuvant chemotherapy studies, possibly because of greater baseline tumor necrosis in squamous cell carcinomas (29). However, the pCR rates of squamous and nonsquamous NSCLC to neoadjuvant nivolumab plus chemotherapy were similar in the CheckMate 816 study, with 25.3% in squamous and 22.8% in nonsquamous. Therefore, more studies are needed to investigate whether the efficacy of neoadjuvant immunotherapy varies against squamous and nonsquamous NSCLC.

In terms of treatment course before surgery, most previous studies choose 2 to 4 cycles. The neoadjuvant single-agent
immunotherapy in CheckMate159 and LCMC3, was performed for two cycles (12, 30). Neoadjuvant immunotherapy combined with chemotherapy in NADIM and CheckMate 816, or a combination of two checkpoint inhibitors in NEOSTAR, was performed for three to four cycles (13, 17, 31). In our study, 41 (65.1%) patients received two cycles of preoperative treatment, 18 (28.6%) patients received three cycles, and only four patients received four cycles of treatment (Table 1). In terms of efficacy (Table 3), further comparing the difference between 2 cycles treatment and 3-4 cycles treatment, we found no statistical correlation (data not shown). In determining the best neoadjuvant treatment course, various factors are taken into

### TABLE 3 Association between clinical characteristics and pathological response.

| Characteristic                          | MPR/pCR (n=42) | Non-MPR (n=21) | P Value | pCR (n=25) | Non-pCR (n=38) | P Value |
|----------------------------------------|----------------|----------------|---------|------------|----------------|---------|
| Age, years                             |                |                |         |            |                |         |
| <65                                    | 21 (50%)       | 14 (67%)       | 0.21    | 13 (52%)   | 22 (58%)       | 0.65    |
| ≥65                                    | 21 (50%)       | 7 (33%)        |         | 12 (48%)   | 16 (42%)       |         |
| Sex                                    |                |                |         |            |                |         |
| Female                                 | 3 (7%)         | 5 (24%)        | 0.061   | 2 (8%)     | 6 (16%)        | 0.36    |
| Male                                   | 39 (93%)       | 16 (76%)       |         | 23 (92%)   | 32 (84%)       |         |
| ECOG PS                                |                |                |         |            |                |         |
| 0                                      | 9 (21%)        | 8 (38%)        | 0.16    | 6 (24%)    | 11 (29%)       | 0.67    |
| 1                                      | 33 (79%)       | 13 (62%)       |         | 19 (76%)   | 27 (71%)       |         |
| Smoking status                         |                |                |         |            |                |         |
| Never                                  | 28 (67%)       | 11 (52%)       | 0.27    | 18 (72%)   | 21 (55%)       | 0.18    |
| Current/Former                         | 14 (33%)       | 10 (48%)       |         | 7 (28%)    | 17 (45%)       |         |
| Clinical T stage                       |                |                |         |            |                |         |
| T1                                     | 3 (7%)         | 0 (0%)         | 0.78    | 3 (12%)    | 0 (0%)         | 0.22    |
| T2                                     | 13 (31%)       | 7 (33%)        |         | 8 (32%)    | 12 (32%)       |         |
| T3                                     | 15 (36%)       | 7 (33%)        |         | 8 (32%)    | 14 (37%)       |         |
| T4                                     | 11 (26%)       | 7 (33%)        |         | 6 (24%)    | 12 (32%)       |         |
| Clinical N stage                       |                |                |         |            |                |         |
| N0                                     | 14 (33%)       | 4 (19%)        | 0.009   | 10 (40%)   | 8 (21%)        | 0.095   |
| N1                                     | 15 (36%)       | 2 (10%)        |         | 8 (32%)    | 9 (24%)        |         |
| N2                                     | 13 (31%)       | 15 (71%)       |         | 7 (28%)    | 21 (55%)       |         |
| Clinical stage (8th edition)           |                |                |         |            |                |         |
| IIA                                    | 3 (7%)         | 0 (0%)         | 0.027   | 3 (12%)    | 0 (0%)         | 0.047   |
| IIB                                    | 13 (31%)       | 1 (5%)         |         | 8 (32%)    | 6 (16%)        |         |
| IIIA                                   | 19 (45%)       | 12 (57%)       |         | 10 (40%)   | 21 (55%)       |         |
| IIIB                                   | 7 (17%)        | 8 (38%)        |         | 4 (16%)    | 11 (29%)       |         |
| PD-L1 expression                       |                |                |         |            |                |         |
| Negative (<1%)                         | 4 (10%)        | 4 (19%)        | 0.65    | 3 (12%)    | 5 (13%)        | 0.84    |
| Positive (≥1%-49%)                     | 8 (19%)        | 5 (24%)        |         | 6 (24%)    | 7 (18%)        |         |
| Positive (≥50%)                        | 14 (33%)       | 5 (24%)        |         | 6 (24%)    | 13 (34%)       |         |
| NA                                     | 16 (38%)       | 7 (33%)        |         | 10 (40%)   | 13 (34%)       |         |
| Neoadjuvant PD-1 inhibitor regimen     |                |                |         |            |                |         |
| Camrelizumab                           | 27 (64%)       | 10 (48%)       | 0.34    | 17 (68%)   | 20 (53%)       | 0.69    |
| Toripalimab                            | 5 (12%)        | 6 (29%)        |         | 4 (16%)    | 7 (18%)        |         |
| Tislelizumab                           | 6 (14%)        | 2 (10%)        |         | 2 (8%)     | 6 (16%)        |         |
| Sintilimab                             | 4 (10%)        | 3 (14%)        |         | 2 (8%)     | 5 (13%)        |         |
| Neoadjuvant treatment cycles           |                |                |         |            |                |         |
| 2                                      | 29 (69%)       | 12 (57%)       | 0.61    | 15 (60%)   | 26 (68%)       | 0.57    |
| 3                                      | 11 (26%)       | 7 (33%)        |         | 9 (36%)    | 9 (24%)        |         |
| 4                                      | 2 (5%)         | 2 (10%)        |         | 1 (4%)     | 3 (8%)         |         |

MPR, major pathologic response; pCR, pathologic complete response; ECOG PS, Eastern Cooperative Oncology Group performance score; NA, not applicable; PD-1, programmed death 1; PD-L1, programmed death-ligand 1.
FIGURE 4
Sankey diagram of the relationship between pathological response of neoadjuvant therapy in different clinical stages. PD-1, programmed death 1; MPR, major pathologic response; pCR, pathologic complete response.

TABLE 4 Treatment-related adverse events during neoadjuvant treatment (n=63).

| Any grade, n (%) | Grade 1-2, n (%) | Grade 3, n (%) |
|-----------------|-----------------|--------------|
| Any treatment-related adverse event | 62 (98.4) | 62 (98.4) | 21 (33.3) |
| **Hematological toxicities** | | | |
| Anemia | 45 (71.4) | 45 (71.4) | 0 |
| Neutrophil count decreased | 30 (47.6) | 19 (30.2) | 11 (17.5) |
| White blood cell decreased | 20 (31.7) | 15 (23.8) | 5 (7.9) |
| Platelet count decreased | 7 (11.1) | 7 (11.1) | 0 |
| **Nonhematological toxicities** | | | |
| ALT/AST increased | 26 (41.3) | 26 (41.3) | 0 |
| Vomiting | 23 (36.5) | 23 (36.5) | 0 |
| Hypoalbuminemia | 22 (34.9) | 22 (34.9) | 0 |
| Blood bilirubin increased | 16 (25.4) | 16 (25.4) | 0 |
| TSH increased | 13 (20.6) | 13 (20.6) | 0 |
| Pneumonia | 12 (19.0) | 5 (7.9) | 7 (11.1) |
| Hyponatremia | 11 (17.5) | 11 (17.5) | 0 |
| Serum amylase increased | 10 (15.9) | 10 (15.9) | 0 |
| Hyperuricemia | 9 (14.3) | 9 (14.3) | 0 |
| Constipation | 8 (12.7) | 8 (12.7) | 0 |
| Rash | 7 (11.1) | 7 (11.1) | 0 |
| Hypokalemia | 6 (9.5) | 6 (9.5) | 0 |
| Creatinine increased | 6 (9.5) | 6 (9.5) | 0 |
| Anorexia | 5 (7.9) | 5 (7.9) | 0 |
| Fatigue | 3 (4.8) | 3 (4.8) | 0 |
| Alopecia | 2 (3.2) | 2 (3.2) | 0 |
| Diarrhea | 2 (3.2) | 2 (3.2) | 0 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; TSH, thyroid stimulating hormone.
account, including efficacy, timing of surgery, and patient compliance. In order to determine the optimal course of treatment, there is a need for more clinical evidence.

Of the 63 patients included in our study, 43 achieved radiological PR, of which 35 (81.4%) achieved pathological MPR or pCR, we found that there was a positive correlation between the imaging regression and pathological regression (Spearman correlation coefficient = 0.43; P = 0.0004; Figure 3). However, 20 patients were evaluated as radiological SD, with seven (35.0%) achieving pathological MPR or pCR. The primary role of immunotherapy promotes the immune cells to infiltrate the tumor and then kill the tumor cells. Patients may benefit from neoadjuvant immunotherapy without initial tumor shrinkage, which is likely to contribute to immune cells infiltrating the tumor (32).

A long-standing method of evaluating neoadjuvant therapy is to examine the pathological changes after surgery. Major pathological response to neoadjuvant treatment is a potential surrogate endpoint for survival (33). Several studies in NSCLC suggest an association between pCR and survival (HR, 0.49; 95% CI, 0.42–0.57) (34). Of note, resectable NSCLC treated with neoadjuvant chemotherapy shows low rates of pCR (median, 4%; range, 0–16%) (33). In CheckMate 816 of neoadjuvant chemoinmunotherapy, the pCR rate was 24% in the nivolumab–plus-chemotherapy arm and 2.2% in the control arm (odds ratio, 13.94; 99% CI, 3.49 to 55.75), the event-free survival appeared to be longer in patients who had a pCR than those who did not (17). Our study found that neoadjuvant PD-1 inhibitors and chemotherapy resulted in a 66.7% MPR rate and a 39.7% pCR rate. Patients who achieved either an MPR or a pCR might benefit long-term survival. In the future follow-up period, this point will be clarified further. For the 40 patients with available PD-L1 data in our study, there was no correlation between the PD-L1 expression of the primary baseline tumor and pathological regression (Spearman correlation coefficient = -0.131; P = 0.42; Supplementary Figure 1).

In advanced NSCLC, PD-L1 expression is a critical marker to guide treatment selection. Among patients with PD-L1 expression ≥ 50%, PD-1 or PD-L1 inhibitor monotherapy can be selected for first-line treatment (9, 35, 36), and patients with high PD-L1 expression may benefit more from the combined immunotherapy (18, 37). However, in a chemoinmunotherapy neoadjuvant setting, PD-L1 expression is not an ideal therapeutic or prognostic marker, and the results differ in different studies. A benefit with nivolumab plus chemotherapy was seen across PD-L1 subgroups in CheckMate 816 study, with a greater event-free survival benefit in patients with a tumor PD-L1 expression level of 1% or more than in those with a level of less than 1% (18, 37). There was a significant difference in PD-L1 tumor proportion score between patients who had a complete pathological response and those who had an incomplete pathological response in the NADIM study (p=0.042) (13), but PD-L1 staining was not predictive of survival (38).

The association of PD-L1 expression in tumor tissues with the efficacy and prognosis of neoadjuvant immunotherapy is unclear and requires continued studies with a larger sample size. Neoadjuvant immunotherapy for NSCLC requires biomarkers that accurately predict efficacy to select people who benefit (13, 38). A single biomarker may be challenging to meet the clinical needs of the published clinical studies. Combining multiple biomarkers is the future trend, and the best biomarkers to predict the efficacy also need to be explored.

The limitations of our study include, but are not limited to, the bias of a retrospective single cohort study, the small number of patients who were included, and the lack of survival follow-up. Therefore, larger randomized control studies are needed to reduce bias and determine the most effective PD-1 blockades of neoadjuvant therapy. Furthermore, long-term follow-up of these studies will be necessary to define the role of neoadjuvant PD-1 blockade in reducing recurrences and curing resectable cancers. In addition, PD-L1 was detected in some but not all patients. At the same time, the ctDNA and tumor mutational burden were not recorded in our study, and adequate biomarker studies are needed to identify the best predictive biomarkers of response and to correlate the pathologic response of neoadjuvant chemoinmunotherapy.

Neoadjuvant PD-1 inhibitors and chemotherapy are feasible therapies for resectable squamous NSCLC. It was associated with a 66.7% MPR rate, 39.7% pCR rate, and tolerable toxicity.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

This study was approved by the institutional review board (IRB)/ethics committee of Beijing Chest Hospital, Capital Medical University. All patients were fully informed and signed informed consent before starting treatment.

Author contributions

ZL and LS conceived the study. LS, QM, LT, HL, YD, and CS collected the data. LS, HL, and ZL analyzed the data. LS, QM, LT, HL, YD, CS, and ZL interpreted the data. LS and ZL wrote the first draft of the manuscript. All authors read and contributed to the final version of the manuscript and approved its submission for publication.
The reviewer JN declared a shared parent affiliation with the authors to the handling editor at the time of review.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.956755/full#supplementary-material

References

1. Wahbah M, Boreoumand N, Castro C, El-Zeby F, Elhorky M. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol (2007) 11(2):89–96. doi: 10.1016/j.anadiapath.2006.04.006

2. Soldera SV, Leigh NB. Update on the treatment of metastatic squamous non-small cell lung cancer in new era of personalized medicine. Front Oncol (2017) 7:50. doi: 10.3389/fonc.2017.00050

3. Socinski MA, Ohasha C, Gandara D, Hirsch FR, Ronesi P, Bunn PF, et al. Current and emergent therapy options for advanced squamous cell lung cancer. J Thorac Oncol (2018) 13(2):165–83. doi: 10.1016/j.jto.2017.11.111

4. Gandara DR, Hammerman PS, Sos MI, Lara PJ, Hirsch FR. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res (2015) 21(10):2236–43. doi: 10.1158/1078-0432.CCR-14-3039

5. Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in resectable non-small-cell lung cancer (ADJACENT): a randomised, open-label, non-inferiority trial. Lancet (2010) 375(9722):1267–77. doi: 10.1016/S0140-6736(10)60059-1

6. Group NMC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet (2014) 383(9928):1561–71. doi: 10.1016/S0140-6736(13)62159-5

7. Gandla L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-Small-cell lung cancer. N Engl J Med (2018) 379(21):2040–51. doi: 10.1056/NEJMoa1810865

8. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-Small-Cell lung cancer. N Engl J Med (2018) 379(21):2040–51. doi: 10.1056/NEJMoa1810865

9. Muk T, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turin HZ, et al. Pembrolizumab versus chemotherapy for previously untreated PD-L1-positive, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet (2019) 393(10183):1819–30. doi: 10.1016/S0140-6736(18)32409-7

10. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol (2019) 20(7):924–37. doi: 10.1016/S1470-2045(19)30167-6

11. Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodriguez-Abreu D, Hussein M, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial. J Thorac Oncol (2020) 15(6):1351–60. doi: 10.1016/j.jtho.2020.03.028

12. Forde PM, Chafe F, Smith KN, Anagnostou V, Cotrell TR, Hellmann MD, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med (2018) 378(21):1976–86. doi: 10.1056/NEJMoa1716078

13. Provencio M, Nadal E, Insa A, Garcia-Campedo MR, Casal-Rubio J, Domíne M, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol (2020) 21(11):1413–22. doi: 10.1016/S1470-2241(20)30453-8

14. Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol (2020) 15(5):516–26. doi: 10.1016/j.jto.2020.01.017

15. Shu CA, Gainor JF, Awad MM, Chhuian C, Grigg CM, Pabani A, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol (2020) 21(6):786–95. doi: 10.1016/S1470-2241(20)30410-6

16. Rothschild SI, Zippelius A, Ebboulet E, Savic PS, Betticher D, Bettini A, et al. Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous NSCLC: a phase 3 randomized clinical trial. JAMA Oncol (2021) 7(5):610–18. doi: 10.1001/jamaoncol.2021.0366

17. Forde PM, Spicer J, Lu S, Provencio M, Mitsuomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med (2022) 386(21):1973–85. doi: 10.1056/NEJMoa2102170

18. Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, et al. Tisotinumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced squamous non-Small-Cell lung cancer: A phase 3 randomized controlled trial. JAMA Oncol (2017) 3(7):911–17. doi: 10.1001/jamaoncol.2017.0386

19. Zhou C, Wu L, Fan Y, Wang Z, Liu L, Chen G, et al. Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: Results from a randomized, double-blind, phase 3 trial (ORIENT-12). J Thorac Oncol (2021) 16(9):1501–11. doi: 10.1016/j.jtho.2021.04.011

20. Ren S, Chen J, Xu X, Jiang T, Cheng Y, Chen G, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A phase 3 trial. J Thorac Oncol (2021) 16(9):544–57. doi: 10.1016/j.jtho.2021.11.018

21. Detterbeck FC, Bofia DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest (2017) 151(1):193–203. doi: 10.1016/j.chest.2016.01.010

Funding

This study was supported by Beijing Tongzhou District High Level Talent Project (Grant number: YH201910 to ZL and YH201916 to LS).

Acknowledgments

We thank patients and their families for their support and participation in this study. Part of this work was presented as a poster at 2021 World Conference on Lung Cancer, worldwide virtual event, September 8-14 2021.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.956755/full#supplementary-material
22. Cottrell TR, Thompson ED, Forde PM, Stein JE, Duffield AS, Anagnostou V, et al. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). *Ann Oncol* (2018) 29(8):1853–60. doi: 10.1093/annonc/mdy218

23. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* (2009) 45(2):228–47. doi: 10.1016/j.ejca.2008.10.026

24. Felip E, Altorki N, Zhou C, Caozi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower110), a randomised, multicentre, open-label, phase 3 trial. *Lancet* (2021) 398(10308):1344–57. doi: 10.1016/S0140-6736(21)02098-5

25. Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. *Nat Rev Clin Oncol* (2015) 12(9):511–26. doi: 10.1038/nrclinonc.2015.90

26. Chen Q, Fu YY, Yue QN, Wu Q, Tang Y, Wang WY, et al. Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer. *Int J Clin Exp Pathol* (2019) 12(3):774–86.

27. Shen D, Wang J, Wu J, Chen S, Li J, Liu J, et al. Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIIB resectable lung squamous cell carcinoma. *J Thorac Dis* (2021) 13:1760–8. doi: 10.21037/jtd-21-103

28. Ling Y, Li N, Li L, Guo C, Wei J, Yuan P, et al. Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes. *NPJ Precis Oncol* (2020) 4(1):32. doi: 10.1038/s41698-020-00135-2

29. Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H, Chaft JE, et al. Pathologic assessment after neoadjuvant chemotherapy for NSCLC: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma. *J Thorac Oncol* (2019) 14(3):482–93. doi: 10.1016/j.jtho.2018.11.017

30. Rusch V, Chaft J, Johnson B, Wistuba I, Kris M, Lee J, et al. MA04.09 neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC). Updated results from a multicenter study (LCMC3). *J Thorac Oncol* (2018) 13 (10, Supplement):S369. doi: 10.1016/j.jto.2018.08.346

31. Cascone T, William WJ, Weissferdt A, Leung CH, Lin HY, Pater A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. *Nat Med* (2021) 27(3):504–14. doi: 10.1038/s41591-020-01224-2

32. Hodi FS, Hwu WJ, Kelford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. *J Clin Oncol* (2016) 34(13):1510–7. doi: 10.1200/JCO.2015.64.0391

33. Hellmann MD, Chaft JE, William WJ, Rusch V, Puters KM, Kalhor N, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. *Lancet Oncol* (2014) 15(1):e42–50. doi: 10.1016/S1470-2045(13)70334-6

34. Waser NA, Adam A, Schweikert B, Vo L, McKenna M, Breckenridge M, et al. Pathologic response as early endpoint for survival following neoadjuvant therapy (NEO-AT) in resectable non-small cell lung cancer (NSCLC): Systematic literature review and meta-analysis. *Ann Oncol* (2020) 31:S806. doi: 10.1016/j.annonc.2020.08.116

35. Herbst RS, Giaccone G, de Marinis F, Reimnuth N, Vergnenegere A, Barrios CH, et al. Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC. *N Engl J Med* (2020) 383(14):1328–39. doi: 10.1056/NEJMoa1917346

36. Sezer A, Kilickap S, Gumas M, Bondarenko I, Ozuguroglu M, Gogvihli M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. *Lancet* (2021) 397(10274):592–604. doi: 10.1016/S0140-6736(21)00228-2

37. Zhou C, Wang Z, Sun Y, Cao L, Ma Z, Wu R, et al. Sugenamilubam versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial. *Lancet Oncol* (2022) 23(2):220–33. doi: 10.1016/S1470-2045(21)00650-1

38. Provencio M, Serna-Blasco R, Nadal E, Insua A, Garcia-Campelo MR, Casal RJ, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-Small-Cell lung cancer (NADIM phase II trial). *J Clin Oncol* (2022) 40(25):2924–33. doi: 10.1200/JCO.21.02660